查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1634200

全球心律管理设备市场 - 2025 - 2033

Global Cardiac Rhythm Management Devices Market - 2025 - 2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球心律管理设备市场规模达195.3亿美元，预估至2032年将达3,269万美元，2025-2032年预测期间复合年增长率为6.6%。

心律管理设备是专门用于监测、调节和支援心臟功能的医疗设备。这些设备在治疗各种心臟疾病，特别是心律不整方面发挥着至关重要的作用，如果不及时治疗，可能会导致严重的健康併发症。它有 3 种类型：心律调节器、去颤器和心臟再同步治疗 (CRT) 设备。

心律调节器是向心臟传送电脉衝以维持正常心跳的装置。除颤器是在出现危及生命的心律不整时提供电击以恢復正常心律的设备。 CRT 设备有助于协调心室的收缩，并提高心臟衰竭患者的治疗效率。

行业产品发布的主要参与者将推动心律管理设备市场的发展。例如，2023 年10 月，波士顿科学公司推出了LUX-Dx II+ 可插入式心臟监视器(ICM) 系统，这是一种下一代设备，旨在长期监测与心房颤动(AF)、隐源性中风、和晕厥。这项创新系统增强了心臟监测的能力，旨在透过先进技术改善患者护理。这些因素推动了全球心律管理设备市场的扩张。

市场动态：

驱动程式和限制

心血管疾病盛行率上升

全球心律管理设备市场的需求是由多种因素所驱动的。心血管疾病（CVD）盛行率的上升是全球心律管理（CRM）设备市场的重要驱动因素。心血管疾病病例的增加导致对有效监测和治疗解决方案的需求更高，直接影响心律管理设备市场的成长和扩张。

根据世界心臟联盟 2023 年 4 月的资料，心血管疾病已成为全球主要死亡原因。 2021 年，有2050 万人死于心血管疾病，约占全球死亡人数的三分之一，比1990 年记录的1210 万人心血管疾病死亡人数显着增加。诊断出心臟相关问题，医疗保健医疗服务提供者需要有效的工具来持续监测这些患者，从而导致起搏器、除颤器和心臟再同步治疗 (CRT) 系统等设备的使用量增加。

此外，关键参与者的策略（例如伙伴关係和协作）将推动心律管理设备市场的成长。例如，2024 年 1 月，美敦力宣布与 Cardiac Design Labs (CDL) 建立策略伙伴关係，在印度推出并扩大名为 Padma Rhythms 的新型心律监测技术的使用。此次合作旨在透过外部循环记录器 (ELR) 贴片提供全面、长期的心臟监测，从而加强心臟护理。

此外，2023 年 6 月，皇家飞利浦宣布与 BIOTRONIK 建立合作伙伴关係，BIOTRONIK 是一家专注于心血管和血管内疾病的着名医疗器材公司。此次合作旨在扩大飞利浦 SymphonySuite 客户可用的心血管设备范围，增强门诊护理环境（例如办公室实验室 (OBL) 和门诊手术中心 (ASC)）的服务。所有这些因素都需要全球心律管理设备市场。

此外，人口老化的加剧和技术进步预计将在预测期内推动心律管理设备市场的发展。

产品召回

产品召回将阻碍全球心律管理设备市场的成长。全球心律管理设备市场的产品召回，特别是植入式心律转復除颤器 (ICD) 和心臟再同步治疗去颤器 (CRT-D) 的召回，主要是由于与设备故障相关的安全问题。

例如，2023 年7 月，美国食品药物管理局(FDA) 宣布对美敦力(Medtronic) 的植入式心律转復除颤器(ICD) 和心臟再同步治疗去颤器(CRT-D) 进行I级召回，因为这些设备有重大风险。

发生此故障的原因是短路保护功能启动不当，该功能会阻止设备提供必要的电击以纠正危及生命的心律不整。这些召回可能会对依赖这些设备进行救生治疗的患者带来严重的健康风险。

因此，上述因素可能限制全球心律管理设备市场的潜在成长。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 心血管疾病盛行率上升
    • 限制
      • 产品召回
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 专利分析
  • 监管分析
  • SWOT分析
  • 未满足的需求

第 6 章：依产品类型

  • 起搏器
    • 单腔起搏器
    • 双腔起搏器
    • 植入式心律调节器
  • 除颤器
    • 体外去颤器
    • 植入式心臟復律去颤器 (ICD)
    • 经静脉 ICD (T-ICD)
    • 皮下ICD (S-ICD)
  • 心臟再同步治疗 (CRT) 设备
    • CRT-P（起搏）
    • CRT-D（除颤）
  • 其他的
  • 按申请
  • 心臟衰竭
  • 心房震颤
  • 心肌梗塞
  • 心律不整
  • 其他的

第 7 章：最终用户

  • 医院和专科诊所
  • 家庭护理设置
  • 门诊手术中心
  • 其他的

第 8 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 9 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 10 章：公司简介

  • Medtronic
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Abbott
  • Boston Scientific Corporation
  • Biotronik
  • Koninklijke Philips NV
  • Schiller AG
  • ZOLL Medical Corporation
  • Physio-Control, Inc. (Stryker)
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • GE HealthCare

第 11 章：附录

简介目录
Product Code: MD847

The global cardiac rhythm management devices market reached US$ 19.53 billion in 2024 and is expected to reach US$ 32.69 million by 2032, growing at a CAGR of 6.6% during the forecast period 2025-2032.

Cardiac rhythm management devices are specialized medical devices designed to monitor, regulate, and support the functioning of the heart. These devices play a crucial role in managing various heart conditions, particularly arrhythmias, which can lead to serious health complications if left untreated. It is of 3 types: pacemakers, defibrillators, and cardiac resynchronization therapy (CRT) devices.

Pacemakers are devices that deliver electrical impulses to the heart to maintain a regular heartbeat. Defibrillators are devices that provide electric shocks to restore normal heart rhythm in cases of life-threatening arrhythmias. CRT devices help coordinate the contractions of the heart's chambers, improving efficiency in patients with heart failure.

Key players in the industry product launches that would propel this cardiac rhythm management devices market. For instance, in October 2023, Boston Scientific launched the LUX-Dx II+ Insertable Cardiac Monitor (ICM) System, a next-generation device designed for long-term monitoring of arrhythmias associated with conditions such as atrial fibrillation (AF), cryptogenic stroke, and syncope. This innovative system enhances the capabilities of cardiac monitoring and aims to improve patient care through advanced technology. These factors have driven the global cardiac rhythm management devices market expansion.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Cardiovascular Diseases

The demand for the global cardiac rhythm management devices market is driven by multiple factors. The rising prevalence of cardiovascular diseases (CVDs) is a significant driving factor for the global cardiac rhythm management (CRM) devices market. This increase in cases of CVDs leads to a higher demand for effective monitoring and treatment solutions, directly impacting the growth and expansion of the cardiac rhythm management devices market.

According to World Heart Federation data in April 2023, CVDs have been the leading cause of death globally. In 2021, 20.5 million people died from a cardiovascular condition, which accounted for around one-third of all global deaths and was a significant increase from the 12.1 million CVD deaths recorded in 1990. As more individuals are diagnosed with heart-related issues, healthcare providers require effective tools to monitor these patients continuously, leading to an uptick in the adoption of devices like pacemakers, defibrillators, and cardiac resynchronization therapy (CRT) systems.

Furthermore, key players' strategies such as partnerships and collaborations would drive the cardiac rhythm management devices market growth. For instance, in January 2024, Medtronic announced a strategic partnership with Cardiac Design Labs (CDL) to launch and expand access to a novel heart rhythm monitoring technology called Padma Rhythms in India. This collaboration aims to enhance cardiac care by providing comprehensive, long-term heart monitoring through an External Loop Recorder (ELR) patch.

Also, in June 2023, Royal Philips announced a partnership with BIOTRONIK, a prominent medical device company specializing in cardiovascular and endovascular diseases. This collaboration aims to expand the range of cardiovascular devices available for Philips' SymphonySuite customers, enhancing the offerings for outpatient care settings such as office-based labs (OBLs) and ambulatory surgery centers (ASCs). All these factors demand the global cardiac rhythm management devices market.

Moreover, the growing aging population and technological advancements are the factors expected to drive the cardiac rhythm management devices market over the forecast period.

Product recalls

The Product Recalls will hinder the growth of the global cardiac rhythm management devices market. Product recalls in the global cardiac rhythm management devices market, particularly for implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), are primarily driven by safety concerns related to device malfunctions.

For instance, in July 2023, the U.S. Food and Drug Administration (FDA) announced a Class I recall of Medtronic's implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), due to a significant risk associated with these devices.

This malfunction occurs because of inappropriate activation of the short circuit protection feature, which can prevent the device from delivering necessary shocks to correct life-threatening arrhythmias. These recalls can lead to serious health risks for patients who depend on these devices for life-saving therapies.

Thus, the above factors could be limiting the global cardiac rhythm management devices market's potential growth.

Segment Analysis

The global cardiac rhythm management devices market is segmented based on product type, application, end-user, and region.

Product Type:

The cardiac resynchronization therapy (CRT) devices segment is expected to dominate the global cardiac rhythm management devices market share

The cardiac resynchronization therapy (CRT) devices segment holds a major portion of the global cardiac rhythm management devices market share and is expected to continue to hold a significant portion of the global cardiac rhythm management devices market share during the forecast period.

The cardiac resynchronization therapy (CRT) devices segment is expected to hold the largest market share over the forecast period. A CRT device is designed to deliver the issue by sending small electrical impulses to both ventricles. These impulses help the ventricles beat together in a more synchronized pattern, coordinated movement of the fingers and thumb as they flex and curl inward together to form a fist. This synchronization enhances the heart's ability to pump blood more effectively, improving overall cardiac output and ensuring that oxygen and nutrients are delivered efficiently throughout the body.

Cardiac resynchronization therapy (CRT) devices are essential components of the global cardiac rhythm management devices market, particularly in managing heart failure and certain arrhythmias. These devices improve heart contractions, which is crucial for effective cardiac function. The CRT segment is experiencing significant growth owing to multiple factors, including the increasing prevalence of cardiovascular diseases, advancements in technology, and a growing geriatric population.

Furthermore, key players in the industry product launches that would propel this segment's growth in the cardiac rhythm management devices market. For instance, in April 2024, MicroPort CRM launched two new ranges of devices in Europe TALENTIA and ENERGYA. These products include Implantable Cardiac Defibrillators (ICDs) and Cardiac Resynchronization Therapy and Defibrillation devices (CRT-Ds), both featuring advanced Bluetooth connectivity. The integration of Bluetooth technology allows for wireless communication between the devices and healthcare providers. This facilitates tablet-based programming and remote monitoring, improving patient management and follow-up care.

Also, in February 2024, MicroPort CRM announced the launch of two significant products in Japan the GALI SonR Cardiac Resynchronization Therapy and Defibrillation device (CRT-D) and the NAVIGO 4LV left ventricular pacing leads. This launch marks an important advancement in cardiac care technology aimed at improving patient outcomes for individuals with heart rhythm disorders. These factors have solidified the segment's position in the global cardiac rhythm management devices market.

Geographical Analysis

North America is expected to hold a significant position in the global cardiac rhythm management devices market share

The rising incidence of cardiovascular diseases (CVDs), including heart failure, arrhythmias, and coronary artery disease, is a significant driver for the cardiac rhythm management devices market. According to CDC data in October 2024, heart disease is indeed the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. One person dies every 33 seconds from cardiovascular disease. In 2022, 702,880 people died from heart disease. All these factors demand cardiac rhythm management devices.

The increasing burden of cardiovascular diseases (CVDs) is significantly influenced by lifestyle factors such as sedentary behavior, unhealthy dietary habits, and an aging population. As healthcare providers seek advanced technologies to manage these conditions effectively, the cardiac rhythm management (CRM) devices market is poised for substantial growth.

Moreover, in this region, a major number of key players' presence, well-advanced healthcare infrastructure, government initiatives & regulatory support, technological advancements, & investments, and product launches & approvals would propel the cardiac rhythm management devices market growth. For instance, in May 2023, Abbott announced that its Assert-IQ insertable cardiac monitor (ICM) has received clearance from the U.S. Food and Drug Administration (FDA). This new device provides physicians with a robust option for the diagnostic evaluation and long-term monitoring of patients experiencing irregular heartbeats.

Also, in July 2023, Abbott announced that the U.S. Food and Drug Administration (FDA) approved the AVEIR dual chamber (DR) leadless pacemaker system. This innovative device is the world's first dual-chamber leadless pacing system, specifically designed to treat patients with abnormal or slow heart rhythms. Thus, the above factors are expected to drive the cardiac rhythm management (CRM) devices market in the region. Thus, the above factors are consolidating the region's position as a dominant force in the global cardiac rhythm management devices market.

Asia Pacific holds the fastest pace in the global cardiac rhythm management devices market and is expected to hold most of the market share.

The prevalence of cardiovascular conditions, such as arrhythmias and heart failure, is rising in the Asia-Pacific region. This increase is largely attributed to lifestyle changes, urbanization, and an aging population, which collectively heighten the demand for effective cardiac rhythm management solutions. As more individuals are diagnosed with these conditions, the need for advanced devices becomes critical.

The aging demographic in Asia-Pacific countries is particularly susceptible to heart-related issues. As this population segment expands, so does the demand for cardiac devices. Older adults are more likely to experience slow heart rhythms and other cardiovascular diseases, leading to increased healthcare needs and a corresponding rise in device utilization.

Innovations in cardiac device technology, such as leadless pacemakers and remote monitoring systems, are enhancing treatment options and improving patient outcomes. These advancements not only make procedures less invasive but also streamline care delivery, making it more efficient and accessible for patients. Many Asia-Pacific countries are investing significantly in healthcare infrastructure, which facilitates better access to advanced medical technologies. Nations like China and India are expanding their healthcare facilities and services, enabling timely treatment for patients and supporting the adoption of cardiac rhythm management devices.

Furthermore, key players in the region product launches that would drive this global cardiac rhythm management devices market growth. For instance, in November 2024, Abbott launched the AVEIR VR leadless pacemaker in India, specifically designed for patients experiencing slow heart rhythms. This innovative device has received approval from both the Central Drugs Standard Control Organisation (CDSCO) in India and the U.S. Food and Drug Administration (FDA), marking a significant advancement in cardiac care. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global cardiac rhythm management devices market.

Competitive Landscape

The major global players in the cardiac rhythm management devices market include Medtronic, Abbott, Boston Scientific Corporation, Biotronik, Koninklijke Philips N.V., Schiller AG, ZOLL Medical Corporation, Physio-Control, Inc. (Stryker), Shenzhen Mindray Bio-Medical Electronics Co., Ltd., and GE HealthCare among others.

Key Developments

  • In March 2024, Abbott received CE mark approval in Europe for its Assert-IQ insertable cardiac monitor (ICM), which is designed for long-term remote monitoring of patients' heart rhythms for up to six years. This device represents a significant advancement in cardiac care technology, enabling healthcare providers to effectively manage patients experiencing irregular heartbeats, including challenging cases such as atrial fibrillation (AF).
  • In October 2023, MicroPort CRM announced the launch of the ULYS Implantable Cardioverter Defibrillator (ICD) and INVICTA defibrillation lead in Japan. This introduction highlights MicroPort's commitment to advancing cardiac care technology and expanding its product offerings in the global market.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global cardiac rhythm management devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising prevalence of cardiovascular diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Product Recalls
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Pacemakers*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Single Chamber Pacemakers
    • 6.2.4. Dual Chamber Pacemakers
    • 6.2.5. Implantable Pacemakers
  • 6.3. Defibrillators
    • 6.3.1. External Defibrillators
    • 6.3.2. Implantable Cardioverter Defibrillators (ICD)
    • 6.3.3. Transvenous ICD (T-ICD)
    • 6.3.4. Subcutaneous ICD (S-ICD)
  • 6.4. Cardiac Resynchronization Therapy (CRT) Devices
    • 6.4.1. CRT-P (Pacing)
    • 6.4.2. CRT-D (Defibrillation)
  • 6.5. Others
  • 6.6. By Application
  • 6.7. Introduction
    • 6.7.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.7.2. Market Attractiveness Index, By Application
  • 6.8. Heart Failure*
    • 6.8.1. Introduction
    • 6.8.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.9. Atrial Fibrillation
  • 6.10. Myocardial Infraction
  • 6.11. Arrhythmias
  • 6.12. Others

7. By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals & Specialty Clinics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Home Care Settings
  • 7.4. Ambulatory Surgical Centers
  • 7.5. Others

8. By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape

  • 9.1. Competitive Scenario
  • 9.2. Market Positioning/Share Analysis
  • 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

  • 10.1. Medtronic *
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
  • 10.2. Abbott
  • 10.3. Boston Scientific Corporation
  • 10.4. Biotronik
  • 10.5. Koninklijke Philips N.V.
  • 10.6. Schiller AG
  • 10.7. ZOLL Medical Corporation
  • 10.8. Physio-Control, Inc. (Stryker)
  • 10.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 10.10. GE HealthCare

LIST NOT EXHAUSTIVE

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us